Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Edgewise Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 220,000 options to buy @ $7.08, valued at $1.6M
08/18/2023 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 133,333 options to buy @ $7.08, valued at $944k
08/18/2023 4 Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 200,000 options to buy @ $7.08, valued at $1.4M
08/18/2023 4 KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 600,000 options to buy @ $7.08, valued at $4.2M
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
07/14/2023 8-K Quarterly results
06/28/2023 SC 13D/A Novo Holdings A/S reports a 9.6% stake in Edgewise Therapeutics, Inc.
06/16/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Common stock SALES AGREEMENT",
"Re: Registration Statement on Form S-3"
06/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights"
05/03/2023 4 Derakhshan Behrad (Chief Business Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,747 shares @ $8.9049, valued at $15.6k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 MOORE JOHN R (General Counsel) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,897 shares @ $8.9049, valued at $16.9k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 Carruthers R Michael (CFO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,336 shares @ $8.9049, valued at $11.9k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 Russell Alan J (Chief Scientific Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 1,602 shares @ $8.9049, valued at $14.3k
Exercised 5,208 restricted stock units @ $0
05/03/2023 4 Donovan Joanne M. (CMO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 3,254 shares @ $8.9049, valued at $29k
Exercised 10,416 restricted stock units @ $0
05/03/2023 4 KOCH KEVIN (President and CEO) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Sold 3,203 shares @ $8.9049, valued at $28.5k
Exercised 10,416 restricted stock units @ $0
03/07/2023 4 Fox Jonathan C (Director) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 43,731 options to buy @ $9.43, valued at $412.4k
03/07/2023 3 Fox Jonathan C (Director) has filed a Form 3 on Edgewise Therapeutics, Inc.
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors"
02/23/2023 8-K Quarterly results
Docs: "Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights"
02/14/2023 SC 13G/A Cormorant Global Healthcare Master Fund, LP reports a 4.7% stake in Edgewise Therapeutics, Inc.
02/14/2023 SC 13G/A VIKING GLOBAL INVESTORS LP reports a 7% stake in Edgewise Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Flynn James E reports a 6.2% stake in Edgewise Therapeutics, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 13.6% stake in EDGEWISE THERAPEUTICS INC
02/01/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
01/03/2023 4 Semigran Marc (Chief Development Officer) has filed a Form 4 on Edgewise Therapeutics, Inc.
Txns: Granted 300,000 options to buy @ $8.94, valued at $2.7M
11/03/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy